BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

Search

Laboratorios Farmaceuticos Rovi SA

Fechado

SetorSaúde

51.1 -0.1

Visão Geral

Variação de preço das ações

24h

Atual

Mín

50.85

Máximo

51.25

Indicadores-chave

By Trading Economics

Rendimento

-57M

32M

Vendas

199M

434M

P/E

Médio do Setor

18.367

57.333

EPS

0.457

Rendimento de Dividendos

2.25

Margem de lucro

7.411

Funcionários

2,197

EBITDA

40M

138M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+52.15% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

2.25%

2.63%

Próximos Ganhos

7 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-896M

2.5B

Abertura anterior

51.2

Fecho anterior

51.1

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de abr. de 2025, 23:54 UTC

Ações em Alta

Stocks to Watch: Alphabet, Intel, AppFolio

24 de abr. de 2025, 23:51 UTC

Conversa de Mercado

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 de abr. de 2025, 23:46 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

24 de abr. de 2025, 23:46 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 de abr. de 2025, 23:37 UTC

Principais Notícias

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 de abr. de 2025, 23:36 UTC

Principais Notícias

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 de abr. de 2025, 23:13 UTC

Principais Notícias
Ganhos

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 de abr. de 2025, 23:09 UTC

Principais Notícias

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 de abr. de 2025, 23:02 UTC

Aquisições, Fusões, Aquisições de Empresas

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 de abr. de 2025, 23:02 UTC

Aquisições, Fusões, Aquisições de Empresas

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 de abr. de 2025, 22:51 UTC

Principais Notícias
Aquisições, Fusões, Aquisições de Empresas

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 de abr. de 2025, 22:48 UTC

Principais Notícias

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 de abr. de 2025, 22:47 UTC

Conversa de Mercado

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 de abr. de 2025, 22:38 UTC

Conversa de Mercado
Ganhos

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 de abr. de 2025, 22:24 UTC

Ganhos

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 de abr. de 2025, 22:24 UTC

Ganhos

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 de abr. de 2025, 22:24 UTC

Conversa de Mercado
Ganhos

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 de abr. de 2025, 22:23 UTC

Ganhos

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 de abr. de 2025, 22:11 UTC

Conversa de Mercado
Ganhos

Global Equities Roundup: Market Talk

24 de abr. de 2025, 22:11 UTC

Conversa de Mercado
Ganhos

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 de abr. de 2025, 22:09 UTC

Principais Notícias
Ganhos

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 de abr. de 2025, 22:00 UTC

Conversa de Mercado
Ganhos

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 de abr. de 2025, 21:39 UTC

Principais Notícias

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 de abr. de 2025, 21:24 UTC

Principais Notícias
Ganhos

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 de abr. de 2025, 21:24 UTC

Principais Notícias
Ganhos

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 de abr. de 2025, 21:23 UTC

Principais Notícias
Ganhos

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 de abr. de 2025, 21:04 UTC

Ganhos

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 de abr. de 2025, 21:03 UTC

Ganhos

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 de abr. de 2025, 21:03 UTC

Ganhos

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 de abr. de 2025, 21:02 UTC

Ganhos

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Comparação entre Pares

Variação de preço

Laboratorios Farmaceuticos Rovi SA Previsão

Preço-alvo

By TipRanks

52.15% parte superior

Previsão para 12 meses

Média 77.75 EUR  52.15%

Máximo 90 EUR

Mínimo 65.5 EUR

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Laboratorios Farmaceuticos Rovi SA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

2

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

49.58 / N/ASuporte e Resistência

Curto Prazo

Very Strong Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.